

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO		Int'l Appln No.: PCT/GB03/003801
	Int'l Filing Date: 01 Sept 2003		
	Applicant: Alan Crossman et al.		
Filing Date: March 20, 2009		Group Art Unit: 3221	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,322,346	03/1982	Korosi et al.				
	4,452,808	06/1984	Gallagher, Jr.				
	4,513,006	04/1985	Maryanoff et al.				
	4,582,916	04/1986	Maryanoff et al.				
	4,824,860	04/1989	Owen				
	6,200,970	03/2001	Ling et al.				
	6,420,369	07/2002	Marcotte				
	6,559,293	05/2003	Almarsson et al.				
	6,583,172	06/2003	Shank				
	6,649,607	11/2003	Leventer et al.				
FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0138441	08/1988	EP				
	0900568	03/1999	EP				
	99/06408	02/1999	WO				
	01/04122	01/2001	WO				
	02/088096	11/2002	WO				
	02/094189	11/2002	WO				
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Beers et al., "The Merck Manual of Diagnosis and Therpay, 17 th Edition", 1999, Merck Research Laboratories Whitehouse Station, NJ, pp. 1462-1473, XP002267011.					
		Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biliferous Ways in Young Persons", 12/27/02, Abstract, XP002266976.					
		Blanchet et al., "Differing Effects of N-Methyl-D-Asparate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-Phenyl-Tetrahydropyridine Monkeys," JPET, vol. 290, no. 3, 1999, pp. 1034-1040.					
		Brotchie et al., "The Effects of Tofisopam on the Actions Induced by L-DOPA Administration in the MPTP - Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Program No. 165.18, pp. 1-2, XP008026196.					
		Burne et al., "The Contribution of Tremor Studies to Diagnosis of Parkinsonian and Essential Tremor: A Statistical Evaluation," Journal of Clinical Neuroscience, vol. 9, no. 3, 2002, pp. 237-242.					
		Connor, "A Double-Blind Placebo-Controlled Trial of Topiramate Treatment for Essential Tremor," Neurology, 59, 2002, pp. 132-134.					
		Fox et al., "Neural Mechanisms Underlying Peak-Dose Dyskinesia Induced by Levodopa and Apomorphine are Distinct: Evidence from the Effects of the Alpha ₂ Adrenoceptor Antagonist Idazoxan," Movement Disorders, vol. 16, no. 4, 2001, pp. 642-650.					
EXAMINER: /Sahar Javanmard/			DATE CONSIDERED: 11/20/2009				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.							

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5-US-WO	Int'l Appln No.: PCT/GB03/003801 Int'l Filing Date: 01 Sept 2003
	Applicant: Alan Crossman et al.	
	Filing Date: March 20, 2009	Group Art Unit: 3221

		Henry et al., "μ- and δ-Opiad Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease," Experimental Neurology, 171, 2001, pp. 139-146.
		Kanda et al., "Combined Use of the Adenosine A _{2A} Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity by Not Dyskinesia in MPTP-Treated Monkeys," Experimental Neurology, 162, 2000, pp. 321-327.
		Konitsiotis et al., "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys", Neurology, Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187.
		Levine, "Medical Treatment of Essential Tremor and Parkinson's Disease," Geriatrics, vol. 53, issue 5, May 1998, 10 pages.
		Nash et al., "Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease," Experimental Neurology, 165, 2000, pp. 136-142.
		Revutsky et al., "Prophylaxis of Metopathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", Vrachebnoe Delo 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189.
		Skradski et al., "Topiramate Blocks Kainate-Evoke Cobolt Influx into Cultured Neurons," Epilepsia, 41 (Suppl. 1), 2000, pp. S45-S47.
		Solyom et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", Current Pharmaceutical Design 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188.
		Tarnawa et al., "2,3-Benzodiazepine AMPA Antagonists", Restorative Neurology and Neuroscience, 1998, Vol. 13, pp. 41-57, XP008026184.
		Wolters et al., "Parkinson's Disease," Recent Advances in Pharmacotherapy, CMAJ, vol. 140, March 1, 1989, pp. 507-513.
		Answers.com, dyskinesia, http://www.answers.com/topic/dyskinesia , printed 09/11/2008, 4 pages.

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 11/20/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	